Aidoc Secures $150M to Scale Clinical AI in Oncology, Cardiovascular Care

The round was led by General Catalyst and Square Peg, with strategic participation from NVentures-Nvidia’s venture arm, and four major U.S. health systems: Sutter Health, Hartford, Mercy, and WellSpan.

Clinical AI company Aidoc has raised $150 million in new funding to expand its AI-driven decision-support tools in oncology and cardiovascular care.

The round was led by General Catalyst and Square Peg, with strategic participation from NVentures-Nvidia’s venture arm, and four major U.S. health systems: Sutter Health, Hartford, Mercy, and WellSpan.

This latest investment includes a $40 million revolving credit facility, bringing Aidoc’s total funding to $370 million. The company is focused on accelerating its enterprise AI platform, aiOS, and scaling its Clinical AI Reasoning Engine (CARE), which supports clinical decision-making across health systems.

Michael Braginsky, co-founder and CTO of Aidoc, added, “Model accuracy is paramount when touching the core of a physician’s work. Foundation models will soon be as ubiquitous in healthcare as ChatGPT is in general use. Building is an enormous lift—it requires top-tier talent, powerful infrastructure, deep real-world insight, and sustained funding.”

Aidoc currently operates across more than 150 health systems, impacting care for over 45 million patients annually. It plans to reach 100 million patients in the next three years. Two new enterprise-wide rollouts were recently announced at Advocate Health and Sutter Health.

Aidoc’s CARE model underpins FDA-cleared algorithms, including a recently approved CADt tool for rib fracture triage. The company is transitioning all its models to CARE and aims for 90% disease coverage, especially in cancer and cardiovascular areas, within three years.

“Our mission is to reduce diagnostic errors and improve patient outcomes,” said Elad Walach, CEO of Aidoc. “CARE compresses decades of roadmap into years, bringing forward a future where AI supports every patient encounter, helping physicians provide the care they believe their patients deserve.”

Walach also noted, “Today, 69% of our customers are running non-Aidoc models on aiOS, and we’re committed to growing that ecosystem, ensuring each solution we onboard will lead to significant clinical impact.”

Roxanna Gapstur, Ph. D., president and CEO of WellSpan Health, said, “In one year, Aidoc has helped our radiologists analyze more than 200,000 cases, making the work of scanning what can sometimes be thousands of images per case, leading to a significant reduction of critical diagnosis delays.”

The company says it will invest more than $150 million into CARE’s market deployment and integration, supported by collaborations with Nvidia and Amazon Web Services.

Stay tuned for more such updates on Digital Health News